Group 1 - The company, Sanbo Brain Science (301293.SZ), announced its plan to invest in the establishment of the Tianjin Yuanming Haihe Brain Science Venture Capital Partnership, aiming to enhance its clinical diagnosis and treatment capabilities while leveraging capital market advantages [1][2] - The total amount to be raised by the partnership is set at 300 million yuan, with the company committing 57 million yuan of its own funds to subscribe for partnership shares [1] - The partnership will focus on investing in leading enterprises in the brain science field, particularly in areas such as diagnosis, treatment, health management, and medical information technology, aligning with the company's core business in neurological medical services [2] Group 2 - The investment is expected to create synergies between the company's existing medical services and the targeted investments in advanced brain science technologies and related sectors [2] - The collaboration aims to achieve resource complementarity and broaden investment channels, enhancing the company's competitive edge in the market [2]

本次公司参与投资设立基金，一方面可以充分发挥各方优势，实现强强联合、资源互补，为公司带来更 宽阔的投资渠道和发展平台。另一方面，本基金未来聚焦具备临床优势的脑科学领域龙头企业进行投 资，包括但不限于脑疾病的检查与诊断、治疗与监护、健康管理与康复、医疗信息化等方向，重点布局 具有先进技术的脑科学企业及其产业链上下游的细分龙头企业和优质标的，所投方向与公司主业强相 关，可以与公司现有的以神经专科为主的医疗服务业务形成良性协同，为增强三博脑科的持续竞争力添 砖加瓦。 智通财经APP讯，三博脑科(301293.SZ)发布公告，为不断完善公司产业链，不断提升公司的临床诊疗水 平，进一步增强公司的科技赋能，同时为充分利用资本市场平台优势，借助专业投资机构的管理水平和 投资经验，公司拟以有限合伙人身份参与投资设立天津元明海河脑科学创业投资合伙企业(有限合伙)(企 业名称最终以工商管理部门核定为准，以下简称"基金"、"合伙企业")，合伙企业拟募集资金总额为3亿 元，公司拟以自有资金认购5,700万元基金份额。2025年9月9日，公司与天津元明管理咨询合伙企业(有 限合伙)等合作方共同签署了《天津元明海河脑科学创业投资合伙企业 ...

Core Viewpoint - Sanbo Brain Science (301293.SZ) aims to enhance its clinical diagnosis and treatment capabilities by investing in the Tianjin Yuanming Haihe Brain Science Venture Capital Partnership, with a total fundraising target of 300 million yuan, of which the company will contribute 57 million yuan [1] Investment Strategy - The partnership will primarily invest in the brain science sector, focusing on clinical advantages in sub-sectors such as diagnosis, treatment, monitoring, health management, rehabilitation, and medical information technology [1] - The investment strategy emphasizes breakthrough technologies, proprietary intellectual property, and leading-edge brain science enterprises along with their upstream and downstream industry chain [1]

Core Viewpoint - Sanbo Brain Science (301293) announced its intention to invest as a limited partner in the establishment of Tianjin Yuanming Haihe Brain Science Venture Capital Partnership, aiming to raise a total of 300 million yuan [1] Investment Details - The company plans to invest 57 million yuan of its own funds to subscribe for shares in the fund [1] - The fund will primarily focus on investments in the brain science sector, including projects related to the diagnosis and treatment of brain diseases, health management, rehabilitation, and medical information technology [1] Fund Registration - After the completion of fundraising, the partnership will promptly carry out the private fund registration and filing procedures [1]

格隆汇9月9日｜三博脑科公告，公司拟以有限合伙人身份参与投资设立天津元明海河脑科学创业投资合 伙企业(有限合伙)，合伙企业拟募集资金总额为3亿元，公司拟以自有资金认购5700万元基金份额。合 伙企业主要投资于脑科学领域，重点聚焦在具备临床优势的细分赛道，包括但不限于脑疾病的检查与诊 断、治疗与监护、健康管理与康复、医疗信息化等项目标的，重点布局突破技术障碍、拥有自主知识产 权、代表技术前沿的脑科学企业及其产业链上下游的细分龙头企业和优秀企业。合伙期限为十五年，投 资期为自基金成立之日起满三年之日终止。 ...

人民财讯9月9日电，三博脑科（301293）9月9日晚间公告，公司拟以有限合伙人身份参与投资设立天津 元明海河脑科学创业投资合伙企业(有限合伙)，合伙企业拟募集资金总额为3亿元，公司拟以自有资金 认购5700万元基金份额，认缴比例：19%。2025年9月9日，公司与天津元明管理咨询合伙企业(有限合 伙)等合作方共同签署了《天津元明海河脑科学创业投资合伙企业(有限合伙)合伙协议》。合伙企业将主 要投资于脑科学领域，重点聚焦在具备临床优势的细分赛道，包括但不限于脑疾病的检查与诊断、治疗 与监护、健康管理与康复、医疗信息化等项目标的。 ...

证券代码：301293 证券简称：三博脑科 公告编号：2025-037 三博脑科医院管理集团股份有限公司 关于与专业投资机构共同投资设立基金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、对外投资概述 1、为不断完善三博脑科医院管理集团股份有限公司（以下简称"公司"、"三 博脑科"）产业链，不断提升公司的临床诊疗水平，进一步增强公司的科技赋能， 同时为充分利用资本市场平台优势，借助专业投资机构的管理水平和投资经验， 公司拟以有限合伙人身份参与投资设立天津元明海河脑科学创业投资合伙企业 （有限合伙）（企业名称最终以工商管理部门核定为准，以下简称"基金"、"合 伙企业"），合伙企业拟募集资金总额为 3 亿元，公司拟以自有资金认购 5,700 万元基金份额。2025 年 9 月 9 日，公司与天津元明管理咨询合伙企业（有限合 伙）等合作方共同签署了《天津元明海河脑科学创业投资合伙企业（有限合伙） 合伙协议》（以下简称"合伙协议"）。 2、本次对外投资不构成关联交易，亦不构成《上市公司重大资产重组管理 办法》规定的重大资产重组，无需经过公司董事会或股东会的 ...

Group 1 - Brain-computer interface concept stocks experienced a decline at the beginning of trading on September 5, with Innovation Medical hitting the daily limit down [1] - Rock Mountain Technology fell over 7%, while other companies such as Aipeng Medical, Sanbo Brain Science, and Jihua Group also saw significant drops [1]

Market Overview - On September 1, the medical services sector rose by 3.84%, with Yingkang Life leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Top Gainers in Medical Services - Yingkang Life (300143) closed at 12.00, up 12.78% with a trading volume of 544,600 shares and a transaction value of 639 million [1] - Zihua Medicine (600721) closed at 9.85, up 10.06% with a trading volume of 562,700 shares [1] - Innovation Medical (002173) closed at 25.19, up 10.00% with a trading volume of 1,271,700 shares and a transaction value of 3.071 billion [1] - Other notable gainers include Puwis (301257), Baicheng Medicine (301096), and WuXi AppTec (603259) with respective increases of 8.59%, 8.46%, and 8.02% [1] Market Capital Flow - The medical services sector saw a net inflow of 1.699 billion in main funds, while retail funds experienced a net outflow of 1.134 billion [2] - The main funds showed a positive trend in several stocks, particularly WuXi AppTec with a net inflow of 1.087 billion [3] Individual Stock Performance - WuXi AppTec (603259) had a main fund net inflow of 1.087 billion, while retail funds saw a net outflow of 660 million [3] - Innovation Medical (002173) experienced a main fund net inflow of 405 million, with retail funds showing a net outflow of 240 million [3] - Sanbo Brain Science (301293) had a main fund net inflow of 152 million, while retail funds saw a net outflow of 107 million [3]

Summary of Sanbo Brain Science Conference Call Company Overview - **Company**: Sanbo Brain Science - **Industry**: Healthcare, specifically focused on brain science and medical technology Key Financial Metrics - **Net Profit**: 72.01 million yuan in H1 2025, up 10.74% YoY [2][3] - **Operating Cash Flow**: 64.76 million yuan, down 21% YoY [2][3] - **Earnings Per Share**: 0.34 yuan, up 6.25% YoY [2][3] - **Total Assets**: 3.719 billion yuan, up 5.34% YoY [3] - **Net Assets**: 2.338 billion yuan, up 1.73% YoY [3] Hospital Utilization and Expansion - **Kunming New Hospital**: Bed utilization rate at 85%, expected to reach 100% within a year [2][5] - **Xi'an Sanbo**: Expected bed utilization to reach 40% by year-end and 60% by early next year [2][5] - **Beijing Sanbo**: Plans to relocate to a new facility with an expected bed utilization of 80% in the first year [2][5] Impact of Healthcare Policies - **Medicare Cost Control**: Stricter policies may delay hospital revenue by 6 to 12 months [2][6][7] - **Non-Medicare Projects**: Hospitals are leveraging pricing advantages in non-Medicare projects to offset revenue losses [2][6][7] Strategic Initiatives - **Brain Science Investments**: Multi-layered approach including basic research, clinical applications, and industrial investments [2][8] - **Partnerships**: Collaborations with institutions like Tsinghua University to drive research and innovation [2][8] - **Brain-Computer Interface (BCI)**: Focus on integrating biomedical and electronic information technologies for medical applications [2][9][10] Future Growth and M&A Plans - **M&A Strategy**: Targeting specialized and general hospitals in the Yangtze River Delta and Pearl River Delta regions [2][4][11] - **New Hospital Developments**: Plans for new facilities in Hunan, with completion expected by August 2025 [2][12] Technological Advancements - **BCI Experiments**: Successful implementation of the first invasive BCI experiment in Fujian, showing promising results [2][14] - **Investment Funds**: Establishment of funds to support AI and BCI innovations, aiming for long-term growth [2][15] Revenue Projections and Challenges - **Revenue from New Facilities**: Expected revenue increases of 5% to 20% post-relocation for various hospitals [2][18] - **Medicare Revenue Share**: Variations in Medicare revenue share across different hospitals, with specialized hospitals generally having lower shares [2][16] Industry Outlook - **Healthcare Service Development**: Focus on improving basic healthcare service quality and leveraging technology for transformation [2][21] - **Technological Empowerment**: Emphasis on external growth and collaboration with tech firms to enhance service offerings [2][22]